Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization - Total (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Depreciation & Amortization - Total for 6 consecutive years, with $321000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization - Total fell 4.18% to $321000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 13.2% decrease, with the full-year FY2025 number at $1.3 million, down 13.2% from a year prior.
  • Depreciation & Amortization - Total was $321000.0 for Q4 2025 at Akebia Therapeutics, up from $318000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $408000.0 in Q4 2022 to a low of $314000.0 in Q1 2025.
  • A 4-year average of $363384.6 and a median of $364000.0 in 2024 define the central range for Depreciation & Amortization - Total.
  • Peak YoY movement for Depreciation & Amortization - Total: rose 0.76% in 2024, then fell 21.0% in 2025.
  • Akebia Therapeutics' Depreciation & Amortization - Total stood at $408000.0 in 2022, then decreased by 3.43% to $394000.0 in 2023, then dropped by 14.97% to $335000.0 in 2024, then decreased by 4.18% to $321000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Depreciation & Amortization - Total are $321000.0 (Q4 2025), $318000.0 (Q3 2025), and $316000.0 (Q2 2025).